Maximilian Huhn1, Magdolna Tardy1, Loukia Maria Spineli2, Werner Kissling1, Hans Förstl1, Gabriele Pitschel-Walz1, Claudia Leucht3, Myrto Samara1, Markus Dold1, John M Davis4, Stefan Leucht5. 1. Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany. 2. Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, University Campus, Ioannina, Greece. 3. Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany2Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, England. 4. Psychiatric Institute, University of Illinois at Chicago. 5. Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany2Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, England5Institute of Psychiatry, King's College London, London, England.
Abstract
IMPORTANCE: There is debate about the effectiveness of psychiatric treatments and whether pharmacotherapy or psychotherapy should be primarily used. OBJECTIVES: To perform a systematic overview on the efficacy of pharmacotherapies and psychotherapies for major psychiatric disorders and to compare the quality of pharmacotherapy and psychotherapy trials. EVIDENCE REVIEW: We searched MEDLINE, EMBASE, PsycINFO, and the Cochrane Library (April 2012, with no time or language limit) for systematic reviews on pharmacotherapy or psychotherapy vs placebo, pharmacotherapy vs psychotherapy, and their combination vs either modality alone. Two reviewers independently selected the meta-analyses and extracted efficacy effect sizes. We assessed the quality of the individual trials included in the pharmacotherapy and psychotherapy meta-analyses with the Cochrane risk of bias tool. FINDINGS: The search yielded 45,233 results. We included 61 meta-analyses on 21 psychiatric disorders, which contained 852 individual trials and 137,126 participants. The mean effect size of the meta-analyses was medium (mean, 0.50; 95% CI, 0.41-0.59). Effect sizes of psychotherapies vs placebo tended to be higher than those of medication, but direct comparisons, albeit usually based on few trials, did not reveal consistent differences. Individual pharmacotherapy trials were more likely to have large sample sizes, blinding, control groups, and intention-to-treat analyses. In contrast, psychotherapy trials had lower dropout rates and provided follow-up data. In psychotherapy studies, wait-list designs showed larger effects than did comparisons with placebo. CONCLUSIONS AND RELEVANCE: Many pharmacotherapies and psychotherapies are effective, but there is a lot of room for improvement. Because of the multiple differences in the methods used in pharmacotherapy and psychotherapy trials, indirect comparisons of their effect sizes compared with placebo or no treatment are problematic. Well-designed direct comparisons, which are scarce, need public funding. Because patients often benefit from both forms of therapy, research should also focus on how both modalities can be best combined to maximize synergy rather than debate the use of one treatment over the other.
IMPORTANCE: There is debate about the effectiveness of psychiatric treatments and whether pharmacotherapy or psychotherapy should be primarily used. OBJECTIVES: To perform a systematic overview on the efficacy of pharmacotherapies and psychotherapies for major psychiatric disorders and to compare the quality of pharmacotherapy and psychotherapy trials. EVIDENCE REVIEW: We searched MEDLINE, EMBASE, PsycINFO, and the Cochrane Library (April 2012, with no time or language limit) for systematic reviews on pharmacotherapy or psychotherapy vs placebo, pharmacotherapy vs psychotherapy, and their combination vs either modality alone. Two reviewers independently selected the meta-analyses and extracted efficacy effect sizes. We assessed the quality of the individual trials included in the pharmacotherapy and psychotherapy meta-analyses with the Cochrane risk of bias tool. FINDINGS: The search yielded 45,233 results. We included 61 meta-analyses on 21 psychiatric disorders, which contained 852 individual trials and 137,126 participants. The mean effect size of the meta-analyses was medium (mean, 0.50; 95% CI, 0.41-0.59). Effect sizes of psychotherapies vs placebo tended to be higher than those of medication, but direct comparisons, albeit usually based on few trials, did not reveal consistent differences. Individual pharmacotherapy trials were more likely to have large sample sizes, blinding, control groups, and intention-to-treat analyses. In contrast, psychotherapy trials had lower dropout rates and provided follow-up data. In psychotherapy studies, wait-list designs showed larger effects than did comparisons with placebo. CONCLUSIONS AND RELEVANCE: Many pharmacotherapies and psychotherapies are effective, but there is a lot of room for improvement. Because of the multiple differences in the methods used in pharmacotherapy and psychotherapy trials, indirect comparisons of their effect sizes compared with placebo or no treatment are problematic. Well-designed direct comparisons, which are scarce, need public funding. Because patients often benefit from both forms of therapy, research should also focus on how both modalities can be best combined to maximize synergy rather than debate the use of one treatment over the other.
Authors: Stefan Leucht; S Z Levine; M Samara; A Cipriani; J M Davis; T A Furukawa Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-10 Impact factor: 5.270
Authors: Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux Journal: CNS Drugs Date: 2015-08 Impact factor: 5.749
Authors: Daisy R Singla; Brandon A Kohrt; Laura K Murray; Arpita Anand; Bruce F Chorpita; Vikram Patel Journal: Annu Rev Clin Psychol Date: 2017-05-08 Impact factor: 18.561
Authors: Heli Malm; Alan S Brown; Mika Gissler; David Gyllenberg; Susanna Hinkka-Yli-Salomäki; Ian W McKeague; Myrna Weissman; Priya Wickramaratne; Miia Artama; Jay A Gingrich; Andre Sourander Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-03-03 Impact factor: 8.829